These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 19830760

  • 21. Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease.
    Schönemann W, Gallienne E, Ikeda-Obatake K, Asano N, Nakagawa S, Kato A, Adachi I, Górecki M, Frelek J, Martin OR.
    ChemMedChem; 2013 Nov; 8(11):1805-17. PubMed ID: 24115322
    [Abstract] [Full Text] [Related]

  • 22. Fluorescent-tagged sp2-iminosugars with potent β-glucosidase inhibitory activity.
    Aguilar-Moncayo M, García-Moreno MI, Stütz AE, García Fernández JM, Wrodnigg TM, Ortiz Mellet C.
    Bioorg Med Chem; 2010 Nov 01; 18(21):7439-45. PubMed ID: 20889348
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
    Trapero A, Llebaria A.
    Future Med Chem; 2013 Apr 01; 5(5):573-90. PubMed ID: 23573974
    [Abstract] [Full Text] [Related]

  • 27. Gaucher disease.
    Butters TD.
    Curr Opin Chem Biol; 2007 Aug 01; 11(4):412-8. PubMed ID: 17644022
    [Abstract] [Full Text] [Related]

  • 28. Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
    Wang GN, Reinkensmeier G, Zhang SW, Zhou J, Zhang LR, Zhang LH, Butters TD, Ye XS.
    J Med Chem; 2009 May 28; 52(10):3146-9. PubMed ID: 19397268
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase.
    Steet R, Chung S, Lee WS, Pine CW, Do H, Kornfeld S.
    Biochem Pharmacol; 2007 May 01; 73(9):1376-83. PubMed ID: 17217920
    [Abstract] [Full Text] [Related]

  • 33. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
    Atrian S, López-Viñas E, Gómez-Puertas P, Chabás A, Vilageliu L, Grinberg D.
    Proteins; 2008 Feb 15; 70(3):882-91. PubMed ID: 17803231
    [Abstract] [Full Text] [Related]

  • 34. Conformationally-locked N-glycosides with selective β-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease.
    Castilla J, Rísquez R, Cruz D, Higaki K, Nanba E, Ohno K, Suzuki Y, Díaz Y, Ortiz Mellet C, García Fernández JM, Castillón S.
    J Med Chem; 2012 Aug 09; 55(15):6857-65. PubMed ID: 22762530
    [Abstract] [Full Text] [Related]

  • 35. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.
    Takai T, Higaki K, Aguilar-Moncayo M, Mena-Barragán T, Hirano Y, Yura K, Yu L, Ninomiya H, García-Moreno MI, Sakakibara Y, Ohno K, Nanba E, Ortiz Mellet C, García Fernández JM, Suzuki Y.
    Mol Ther; 2013 Mar 09; 21(3):526-32. PubMed ID: 23337983
    [Abstract] [Full Text] [Related]

  • 36. Analysis of the glucocerebrosidase gene and mutation profile in 144 Italian gaucher patients.
    Filocamo M, Mazzotti R, Stroppiano M, Seri M, Giona F, Parenti G, Regis S, Corsolini F, Zoboli S, Gatti R.
    Hum Mutat; 2002 Sep 09; 20(3):234-5. PubMed ID: 12204005
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase.
    Abian O, Alfonso P, Velazquez-Campoy A, Giraldo P, Pocovi M, Sancho J.
    Mol Pharm; 2011 Dec 05; 8(6):2390-7. PubMed ID: 21988669
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.